Linked Life Data

19445928

Source:http://linkedlifedata.com/resource/pubmed/id/19445928

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2009-6-26
pubmed:abstractText
3-Nitropropionic acid inhibits succinate dehydrogenase, complex II enzyme in the mitochondrial respiratory chain that leads to cellular energy deficit and oxidative stress. Huntington's disease is characterized by abnormal body movements (chorea) and cognitive dysfunctions. Rivastigmine, a well known cholinesterase inhibitor used in the management of Alzheimer's disease in a clinical practice. Recent clinical studies suggest the potential role of rivastigmine in the management of Huntington's disease. The present study has been designed to explore the possible role of rivastigmine against 3-nitropropionic acid induced behavioral, biochemical and cellular alterations. Intraperitoneal administration of 3-nitropropionic acid (10 mg/kg for 14 days) caused significant loss in body weight, motor in coordination (locomotor activity and rota rod performance) and poor memory retention in Morris water maze and elevated plus maze performance tasks as compared to vehicle treated animals. Biochemical analysis revealed significant increase in lipid peroxidation, nitrite concentration and depleted superoxide dismutase, catalase levels and alterations in mitochondrial complex enzymes (I, II, IV and MTT assay) in the different regions (striatum, cortex and hippocampus) of rat brain. Rivastigmine (0.5, 1 and 2 mg/kg, orally) once daily treatment for a period of 14 days significantly improved motor performance and cognitive task in both Morris water maze and elevated plus maze tests. Further, rivastigmine treatment significantly attenuated oxidative damage and improved mitochondrial complexes enzyme activities in different regions (striatum, cortex and hippocampus) of rat brain. The results show that rivastigmine could be used as an effective therapeutic agent in the management of Huntington's disease and related conditions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1879-0712
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
615
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
91-101
pubmed:meshHeading
pubmed-meshheading:19445928-Administration, Oral, pubmed-meshheading:19445928-Animals, pubmed-meshheading:19445928-Behavior, Animal, pubmed-meshheading:19445928-Brain, pubmed-meshheading:19445928-Brain Chemistry, pubmed-meshheading:19445928-Cholinesterase Inhibitors, pubmed-meshheading:19445928-Corpus Striatum, pubmed-meshheading:19445928-Huntington Disease, pubmed-meshheading:19445928-Lipid Peroxidation, pubmed-meshheading:19445928-Male, pubmed-meshheading:19445928-Maze Learning, pubmed-meshheading:19445928-Mitochondria, pubmed-meshheading:19445928-Motor Activity, pubmed-meshheading:19445928-Neuroprotective Agents, pubmed-meshheading:19445928-Nitrites, pubmed-meshheading:19445928-Nitro Compounds, pubmed-meshheading:19445928-Oxidative Stress, pubmed-meshheading:19445928-Phenylcarbamates, pubmed-meshheading:19445928-Propionic Acids, pubmed-meshheading:19445928-Rats, pubmed-meshheading:19445928-Rats, Wistar, pubmed-meshheading:19445928-Rotarod Performance Test
pubmed:year
2009
pubmed:articleTitle
Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
pubmed:affiliation
Pharmacology division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh-160014, India.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't